Achieve Life Sciences, Inc. (ACHV)
- Previous Close
4.5100 - Open
4.5700 - Bid 4.3700 x 100
- Ask 4.4700 x 100
- Day's Range
4.3500 - 4.5800 - 52 Week Range
3.0300 - 10.3000 - Volume
82,074 - Avg. Volume
97,020 - Market Cap (intraday)
151.051M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5000 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.75
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
www.achievelifesciences.comRecent News: ACHV
Performance Overview: ACHV
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHV
Valuation Measures
Market Cap
152.42M
Enterprise Value
153.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
38.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.03%
Return on Equity (ttm)
-869.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.82M
Diluted EPS (ttm)
-1.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
15.55M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.43M